Great news to wake up to... BRI-OM = onto Phase 3! Hopefully Mr Market agrees.
Noticed Ph3 protocol will be testing both Q3 (3x weekly) and Q1 (weekly) Cisplatin even though strongest signal in Ph2 was in 3x weekly - Nice – as that opens us up *all* HNC patients... 65k in US, 750k worldwide... Soligenix Ph3 limited Ph3 to 3x weekly.
Plus we have the oral rinse/sachet advantage – YUGE to borrow from you. Makes so much easier to eventually transition to other OM-related indications if we get the HNC label (think like 30-40% of all cancer patients will develop OM, HSCT obv the next behind HNC)
Galera has Breakthrough, but is IV. Fast Track almost as good as BTD, which I did think we’d get (mea culpa) – maybe our trial size was what worked against on that front, plus the 1x weekly data.
re PRU results - confirmation Mr Market was right as other have said. Hope most of that Fail was baked into price. 2 multi-indication horses still in the stable (BRI/KEV) and hopefully we get the $$$ to let them run free, run wild.
To that point, now just need a BRI-OM (or more) Deal to get us to a more appropriate valuation reflective of Ph3 asset, pipeline.
News 
Market Data 
Discover 
